Skip to content

A&O advises Carlyle and PAI Partners on the financing of their acquisition of Theramex from CVC

Allen & Overy has advised global investment firms Carlyle (NASDAQ: CG) and PAI Partners on the financing aspects of their acquisition of Theramex, the leading global specialty pharmaceuticals company focused on women’s health, from CVC Capital Partners.

Theramex was created following the carve-out of a portfolio of women’s health pharma products in 2018, and has subsequently developed into one of the largest specialty pharma platforms dedicated to women and their health. The company now serves more than six million women in 57 countries across EMEA, APAC and South America.

The acquisition will enable Theramex to expand its diverse suite of products across existing and adjacent therapeutic areas and accelerate international expansion. Healthcare is strategically important to both firms, with Carlyle having invested USD15 billion to date in healthcare and with healthcare being one of PAI’s four core sectors of focus. 

Partners Adam Zecharia and Robin Harvey led the deal from London with senior associate Sherry Khalili and associates Andreas Georgiades, Dhruv Mairal and Sykes Mitchell.

High yield partner John Kicken and associate Sampada Bannurmath also advised on the transaction.